key: cord-0980052-xcdqtcgz authors: Jutel, Marek; Torres, Maria J.; Palomares, Oscar; Akdis, Cezmi A; Eiwegger, Thomas; Untersmayr, Eva; Barber, Domingo; Zemelka‐Wiacek, Magdalena; Kosowska, Anna; Palmer, Elizabeth; Vieths, Stefan; Mahler, Vera; Canonica, Walter G.; Nadeau, Kari; Shamji, Mohamed H; Agache, Ioana title: COVID‐19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations date: 2022-03-18 journal: Allergy DOI: 10.1111/all.15252 sha: 41290d91c4b4be9ed80d3964c84c7c89bb5440b3 doc_id: 980052 cord_uid: xcdqtcgz Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen‐specific manner via allergen immunotherapy (AIT) or in an endotype‐driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)‐5 and IL‐4/IL‐13 or non‐type 2 response: anti‐cytokine antibodies and B‐cell depletion via anti‐CD20. Coronavirus disease 2019 (COVID‐19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS‐CoV‐2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID‐19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID‐19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID‐19 infection, of COVID‐19 vaccine, of AIT and of biologicals and considered the data published for other anti‐infectious vaccines administered concurrently with AIT or biologicals. The immune system protects the host against pathogens while maintaining tolerance against self-and innocuous non-self-antigens. On the contrary, NET formation is associated with lung diseases, especially acute respiratory distress syndrome (ARDS). In severe SARS-CoV-2 infection, the uncontrolled progressive inflammation likely induces intense crosstalk between NET-releasing neutrophils and Mφ IL-1β secretion, which may lead to further complications. 8 CD8 + T cells directly neutralize infected cells, and CD4 + T cells help B cells initiate a humoral response against the pathogen. T cells play an essential role in developing virus-specific memory CD8 + and CD4 + T cells. [9] [10] [11] SARS-CoV-2-specific CD8 + and CD4 + T cells have recently been identified in ~70% and 100% of patients following SARS-CoV-2 infection, respectively. Delayed development of adaptive responses along with prolonged virus clearance has been reported in cases of severe SARS-CoV-2 infection. 12 The mechanisms related to lymphocytopenia are still unknown in SARS-CoV-2 infection. Moreover, as with SARS-CoV-2, alteration in antigenpresenting cells (APC) function followed by impairment of T cell stimulation may lead to the ineffective and delayed formation of virus-specific T cells. [13] [14] [15] Data on NK cell count in COVID-19 patients are variable. Functional depletion of NK cells and CD8 + T cells has been described in relation to severe SARS-CoV-2 infection. 16 The number of the regulatory T cells (Treg) is reduced during SARS-CoV-2 infection. 17 The intense cytokine response can induce apoptosis of T cells. 18 Infection with human SARS-CoV-2 activates the immune mechanisms of B and Th cells, with production of neutralizing antibodies (nAb), that binds specifically to surface structures on the virus, preventing them from interacting with the host cells. Moreover, nAb can Immune modulatory responses of COVID-19 vaccination, allergen immunotherapy and Biologicals T2 responses. either interfere with the virus infectivity or binding antibodies (BAbs), which bind specifically to the virus, but do not interfere with it infectivity. Most of the SARS-CoV-2 neutralizing antibodies target the glycoprotein S (or spike (S) protein) receptor-binding domain (RBD), which engages the host receptor angiotensin-converting enzyme 2 (ACE2) for viral entry. 19 The antibody response occurs 4-8 days after the onset of COVID-19 symptoms by IgM. 20 Early humoral response is dominated by IgA antibodies, 21 and plasmablasts were detected shortly after the onset of symptoms and peaked in the third week of illness. Neutralizing IgA serum titrants decreased notably after 1 month of the onset of symptoms but remained detectable in saliva up to 49 to 73 days post-symptoms. 22 The development of mucosal IgA can prevent re-infection with SARS-CoV-2, while circulating IgA can contribute to the systemic neutralization of SARS-CoV-2 and the reduction of inflammation during active infection. 23 SARS-CoV-2 IgG nAb specific to the S protein decrease after 5-8 weeks but are still detectable up to 8 months after infection. 24 For this reason, passive transfer of human serum obtained during convalescence was suggested as a therapeutic approach. 25 However, low affinity or suboptimal levels of IgG may increase viral entry through IgG binding to the Fcγ receptor (FcγR) expressed on immune cells. This mechanism may induce the release of inflammatory cytokines and contribute to the CRS associated with severe COVID-19. 26 The potential contribution of the B cell population to COVID-19 pathology has not yet been fully elucidated. The main challenges with B cell responses to SARS-CoV-2 is the duration of the antibody response (IgG) after the infection and the ability of SARS-CoV-2-specific memory B cells to expand or replenish the plasma cell compartment after re-infection 27 ( Figure 1 ). In COVID-19 patients, S protein-specific memory B cells were more frequent at 6 months than at 1 month after symptom onset and the IgG to the S protein was relatively stable over 6 months. 28 Figure 1 created with BioRender.com. The major mechanism of protection against viral infection triggered by the licensed vaccines relies on generating antigen-specific memory cells, which when re-exposed to the pathogen, will quickly create a T and B cell response that persists over time. GCs formation and select affinity-matured GCs B cells, which may further differentiate into LLPC or Bmem. T FH cells may differentiate towards the Th1 or Th2 phenotype, which will affect the switching of antibodies produced by LLPC to Th1-or Th2-dependent antibody class. 34 Other subsets of CD4 + T cells may serve various essential functions, including facilitating optimal CD8 T-cell responses. In addition, cytotoxic CD8 + T cells responsible for the direct killing of pathogen-infected cells by releasing molecules such as granzyme and perforin provide an important 'safety net' that has to be created by vaccination in case protective antibodies do not completely control the viral infection. Two RNA-based COVID-19 vaccines have been the first to be approved globally, and these were produced by BioNTech/Pfizer and Moderna, respectively. 36 The BioNTech/Pfizer vaccine BNT162b2 is a lipid nanoparticle formulated nucleoside-modified messenger RNA (modRNA) encoding SARS-CoV-2 full-length S glycoprotein modified by 2 proline mutations to lock it in the prefusion conformation. [37] [38] [39] [40] [41] [42] The Moderna vaccine mRNA-1273 is also a lipid nanoparticleencapsulated mRNA-based vaccine that encodes the prefusion sta- Substantially higher serum-neutralizing titres were achieved seven days after the booster dose. On Day 43 (21 days after the boost), the neutralizing and RBD-binding start decreasing. It should be mentioned that, the absolute mean titer of neutralizing Ab in a group over the age of 80 years remained lower than the < 60 years of age group. After the second vaccination, 31.3% of the elderly had no detectable neutralizing Ab. 49 The intensity of RBD-specific CD4 + T cell responses correlated positively with both RBD-binding IgG and SARS-CoV-2-nAb titres. The intensity of RBD-specific CD8 + T cell responses correlated positively with vaccine-induced CD4 + T cell responses but did not significantly correlate with SARS-CoV-2 nAb titres. RBD-specific CD4 + T cells secreted IFNγ, IL-2 or both, but in most individuals, they did not secrete IL-4. Similarly, fractions of RBD-specific CD8 + T cells secreted IFNγ and IL-2. Five vaccinated participants were stimulated ex vivo with overlapping RBD peptides and produced the pro-inflammatory cytokines TNF, IL-1β and IL-12p70, but neither IL-4 nor IL-5. In summary, these findings indicate that BNT162b1 induces functional and pro-inflammatory CD4 + and CD8 + T cell responses with detection of IFNγ, IL-2 and IL-12p70, but not IL-4 or IL-5, which reveals a favourable Th1 profile and the absence of a potentially deleterious type 2 immune response. 50 With this in mind, antigen-specific T cell responses were characterized in mice 12 and 28 days after BNT162b vaccine immunization. A strong IFNγ producing CD4 + and CD8 + T cell responses, and a high fraction of CD8 + T cells that produced IL-2 were observed. Moreover, 28 days after immunization with 1μg BNT162b2, splenocytes revealed high levels of Th1 cytokine production (IL-2 or IFNγ), along with undetectable levels of Th2 cytokines IL-4, IL-5 or IL-13. In addition, one immunization with BNT162b2 induced high dose leveldependent RBD-and S1-binding serum IgG titres. Furthermore, IgG elicited by BNT162b2 revealed a strong binding affinity for the recombinant RBD target antigen. ChAdOx1 initial course and all except one after BNT162b2, with no safety concerns. 82, 83 In summary, the levels of antibodies (binding Ab specific to S-2P AIT is an intervention for allergic diseases and asthma-inducing tolerance to the sensitizing allergen eliciting the symptoms. 84 By continuous administration of high amount relevant allergen(s), a tolerogenic immune response is generated. Main mechanisms involve early effector cell desensitization and progressive onset of a regulatory B and T cell response followed by significant decreases in allergen-specific type 2 especially Th2 cells and type 2 ILCs in circulation and the affected tissue. [85] [86] [87] Effective AIT has been shown to reverse the Th2 dominance with increased IFNγ production and reduction in Th2 cytokines. 88 Although AITinduced changes are antigen-specific, recent data support a positive effect in the overall rebalance of Th2-skewed innate immune system. 89, 90 does not considerably increase in severity in allergic disease, such as rhinitis, urticaria and atopic dermatitis or even asthma, if controlled under background treatment. 91, 92 The immunological mechanisms of AIT and COVID-19 vaccine do not seem to interfere as both primarily target the immune system in a specific, non-overlapping manner. The effect of AIT on the effector cell desensitization, especially mast cell desensitization, is rather limited, antigen/allergen specific and occurs early during AIT. 93 However, mast cells are not considered to be relevant for antiviral immune response. Biologicals represent an essential cornerstone in the management of non-type 2 inflammatory diseases. Anti-cytokine antibodies are applied in patients with inflammatory bowel disease, rheumatic diseases or inflammatory skin diseases. 105 These antibodies modulate cytokine dysregulation being involved in disease onset and progression. In autoimmunity, B-cell depletion via anti-CD20 biological is used in not only organ specific but also systemic diseases for elimination of auto-reactive B cells and plasma cells. 106 AIT is an effective treatment for allergic rhinitis with and without asthma and is associated with reduced clinical symptoms, the need for rescue medication and disease exacerbation. AIT induces long term clinical and immunological tolerance where clinical benefit is observed beyond the cessation of treatment administration. [109] [110] [111] Safety and efficacy are essential for an allergic patient undergoing AIT who intend to receive an anti-infectious vaccine (AIV). Current guidelines recommend that the administration of AIT and AIV should be separated by a minimum of a 7-day interval to avoid potential interfering reactions. 112, 113 However, this is based on a pragmatic approach rather than on existing evidence from clinical studies. A retrospective analysis of 875 subjects showed that patients receiving AIT and AIV on the same day did not experience more systemic reactions than those receiving AIT alone. 114 Data on AIV impact on AIT suggest that booster vaccines can be effectively and safely administered in allergic patients receiving AIT. 115 From the mechanistic point of view, AIT and COVID-19 immune responses do not seem to interfere negatively ( Table 1) . AIT patients might even benefit by rebalancing the innate immune system and favouring protective responses ( Table 2 , Figures 2 and 3) . im ? [159, 165, 166, 167, 168] (Continues) inflammation. Moreover, T1 polarization may provide an additive effect to AIT and biologicals which target T2 immunity. It can be postulated that the suppression of T2 immunity and induction of Treg cells observed during AIT may increase the risk of early inflammatory adverse reactions by a short interval. Moreover, the reduction in T2 immunity may potentially suppress IFNγ, which was released by CD4 + and CD8 + after vaccination and decrease the risk of anaphylaxis. AIT, allergen immunotherapy; IFNγ, interferonγ; T1, type 1 immunity; T2, type 2 immunity; Treg, T regulatory cells. Figure 3 created with BioRender.com. Five mAbs are currently approved for severe type 2 asthma: omalizumab, mepolizumab, benralizumab, reslizumab and dupilumab. 116 The use of these mAbs during the COVID-19 pandemic is considered safe, as they do not increase the rate of viral transmission. 117 (Table 3) . Recommendation 2: A 7-day interval between administration of a biological targeting the T2 immune response and COVID-19 vaccine is recommended to unequivocally assign potential side effects of each other. Applying biologicals in non-type 2 (non-T2) inflammatory diseases In the context of inflammatory diseases, TNFα suppresses B and T cell function, which can be restored by anti-TNFα treatment. [145] [146] [147] Undesired Further evidence from disease registries and other realworld data bases must be accumulated in order to refine current recommendations. We thank Anna Gandaglia for her administrative support in the coordination of all co-authors and supporting the EAACI ROC. Type 2 immunity in the skin and lungs The 3 major types of innate and adaptive cell-mediated effector immunity Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 Interaction of SARS and MERS coronaviruses with the antiviral interferon response Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine 'storm' and risk factor for damage of hematopoietic stem cells Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan Targeting potential drivers of COVID-19: Neutrophil extracellular traps Counting antigenspecific CD8 T cells: a reevaluation of bystander activation during viral infection Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection Human immunopathogenesis of severe acute respiratory syndrome (SARS) Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice Functional exhaustion of antiviral lymphocytes in COVID-19 patients Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease IgA antibodies and IgA deficiency in SARS-CoV-2 infection IgA dominates the early neutralizing antibody response to SARS-CoV-2 IgA and FcαRI: pathological roles and therapeutic opportunities Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival The convalescent sera option for containing COVID-19 The potential danger of suboptimal antibody responses in COVID-19 Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence Correlates of protection induced by vaccination T follicular helper cell biology: a decade of discovery and diseases Follicular helper T cells SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines (Basel) From vaccines to memory and back COVID-19 vaccines: modes of immune activation and future challenges BNT162b vaccines protect rhesus macaques from SARS-CoV-2 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers Age-dependent Immune response to the Biontech/Pfizer BNT162b2 Coronavirus disease 2019 vaccination COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses Covid-19 vaccines: delivering protective immunity mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants mRNA-1273 study group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults mRNA-1273 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 mRNA-1273 study group. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination mRNA-1273 study group. An mRNA vaccine against SARS-CoV-2 -preliminary report SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight U.S. Locations Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. medRxiv Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). Sci Rep Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK SARS-CoV-2 antibody response after ChAdOx1 nCoV-19 vaccination in persons with previous SARS-CoV-1 infection Oxford COVID Vaccine Trial Group. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses The COVID-19 vaccine development landscape Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial Placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by Sinovac -PROFISCOV: a structured summary of a study protocol for a randomised controlled trial observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18-59 years in Indonesia. Registri Penyakit Indonesia. Retrieved 15 A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) Viral targets for vaccines against COVID-19 Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial The race for coronavirus vaccines: a graphical guide Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials Protection of BNT162b2 vaccine booster against Covid-19 in Israel Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics Persistent regulatory Tcell response 2 years after 3 years of grass tablet SLIT: Links to reduced eosinophil counts, sIgE levels, and clinical benefit Tolerance mechanisms in allergen immunotherapy Recent developments and highlights in immune monitoring of allergen immunotherapy Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan ARIA-MASK Study Group. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement Emerging roles of innate lymphoid cells in inflammatory diseases: clinical implications Tezepelumab in Adults with Uncontrolled Asthma Longitudinal analyses reveal immunological misfiring in severe COVID-19 Thymic stromal lymphopoietin limits primary and recall CD8 + T-cell anti-viral responses TSLP-driven chromatin remodeling and trained systemic immunity after neonatal respiratory viral infection Type 2 interleukin-4 receptor signaling in neutrophils antagonizes their expansion and migration during infection and inflammation Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection Reduced interleukin-4 receptor α expression on CD8+ T cells correlates with higher quality anti-viral immunity Impact of genetic variants in IL-4, IL-4 RA and IL-13 on the anti-pneumococcal antibody response IL-4 and IL-13 receptors: roles in immunity and powerful vaccine adjuvants Immunological aspects related to viral infections in severe asthma and the role of omalizumab Modulating Th2 cell immunity for the treatment of asthma Managing risks with biologics B cell targeted therapies in autoimmune disease Monoclonal antibody therapy of cancer Checkpoint inhibition through small molecule-induced internalization of programmed deathligand 1 Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers Immunological responses and biomarkers for allergen-specific immunotherapy against inhaled allergens Using a gluten oral food challenge protocol to improve diagnosis of wheat-dependent exerciseinduced anaphylaxis Vaccination during concurrent subcutaneous immunotherapy: safety of simultaneous application Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 bias. Vaccine EAACI Biologicals Guidelines-Recommendations for severe asthma COVID-19 in a patient with severe asthma treated with Omalizumab COVID-19, severe asthma, and biologics Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy Eosinopenia <100/μL as a marker of active COVID-19: An observational prospective study Eosinophils capture viruses, a capacity that is defective in asthma Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines -recommendations on the use of biologicals in severe asthma Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis ALIZE study investigators. Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab SNIFFLE-4 Study Investigators. Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma Epidemic yellow fever immunization: Is that a problem to Omalizumab treatment? Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells TLR9-and FcepsilonRImediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3 + Tregs Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies -A Danish population-based cohort study Musc-19 Study Group. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review COVID-19 in ocrelizumabtreated people with multiple sclerosis Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study A molecular mechanism for TNF-α-mediated downregulation of B cell responses Modulation of T lymphocyte replicative senescence via TNF-{alpha} inhibition: role of caspase-3 Down-regulation of CD28 expression by TNF-alpha Immunogenicity of quadrivalent influenza vaccine for patients with inflammatory bowel disease undergoing immunosuppressive therapy Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease Assessment of anti-HBs antibody concentration in children with juvenile idiopathic arthritis treated with biological drugs, vaccinated against viral type B hepatitis in infancy Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a singleblind randomized phase IV trial Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations High immunogenicity to influenza vaccination in Crohn's disease patients treated with ustekinumab. Vaccines (Basel) Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab Secukinumab does not impair the immunogenic response to the influenza vaccine in patients Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition Vaccination and immune checkpoint inhibitors: does vaccination increase the risk of immune-related adverse events? A systematic review of literature Draft landscape and tracker of COVID-19 candidate vaccines SARS-CoV-2 inactivated vaccine (Vero cells) shows good safety in repeated administration toxicity test of Sprague Dawley rats 2019nCoV-302 Study Group. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial Development of an Inactivated Vaccine against SARS CoV-2. Vaccines Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, doubleblind, placebo-controlled trial Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, doubleblind, placebo-controlled, phase 1 and 2 trials Preclinical immune response and safety evaluation of the protein subunit vaccine nanocovax for COVID-19 COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations Pediatric Allergy and Clinical Immunology Department Frederic de Blay, Division of Allergy and Immunology Sergio Bonini, National Heart and Lung Institute (NHLI)